ArticleFrontiers in immunology2022

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up.

Simona Rolla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.